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Van der Hoek, Joost, Marlijn Waaijers, Peter M. van Koetsveld,
Diana Sprij-Mooij, Richard A. Feelders, Herbert A. Schmid, Phil-
ippe Schoeffter, Daniel Hoyer, Davide Cervia, John E. Taylor, Mi-
chael D. Culler, Steven W. J. Lamberts, and Leo J. Hofland. Distinct
functional properties of native somatostatin receptor subtype 5 compared
with subtype 2 in the regulation of ACTH release by corticotroph tumor
cells. Am J Physiol Endocrinol Metab 289: E278–E287, 2005. First
published March 15, 2005; doi:10.1152/ajpendo.00004.2005.—In a se-
ries of human corticotroph adenomas, we recently found predominant
mRNA expression of somatostatin (SS) receptor subtype 5 (sst5).
After 72 h, the multiligand SS analog SOM230, which has a very high
sst5 binding affinity, but not Octreotide (OCT), significantly inhibited
basal ACTH release. To further explore the role of sst5 in the
regulation of ACTH release, we conducted additional studies with
mouse AtT-20 cells. SOM230 showed a 7-fold higher ligand binding
affinity and a 19-fold higher potency in stimulating guanosine 5-O-
(3-thiotriphosphate) binding in AtT-20 cell membranes compared
with OCT. SOM230 potently suppressed CRH-induced ACTH re-
lease, which was not affected by 48-h dexamethasone (DEX) pretreat-
ment. However, DEX attenuated the inhibitory effects of OCT on
ACTH release, whereas it increased the inhibitory potency of BIM-
23268, an sst5-specific analog, on ACTH release. Quantitative PCR
analysis showed that DEX lowered sst2A2B mRNA expression sig-
nificantly after 24 and 48 h, whereas sst5 mRNA levels were not
significantly affected by DEX treatment. Moreover, Scatchard analy-
ses showed that DEX suppressed maximum binding capacity (Bmax)
by 72% when 125I-Tyr3-labeled OCT was used as radioligand,
whereas Bmax declined only by 17% when AtT-20 cells were treated
with [125I-Tyr11]SS-14. These data suggest that the sst5 protein,
compared with sst2, is more resistant to glucocorticoids. Finally, after
SS analog preincubation, compared with OCT both SOM230 and
BIM-23268 showed a significantly higher inhibitory effect on CRH-
induced ACTH release. In conclusion, our data support the concept
that the sst5 receptor might be a target for new therapeutic agents to
treat Cushing’s disease.
Cushing’s disease; adrenocorticotropic hormone; glucocorticoid
CUSHING’S DISEASE, the pituitary-dependent form of Cushing’s
syndrome, is the hypercortisolemic state secondary to excess or
dysregulated ACTH secretion caused by an ACTH-secreting
pituitary adenoma (36). The significant associated morbidity,
such as increased tissue fragility, poor wound healing, hyper-
tension, and diabetes mellitus, demands a proper medical
intervention (1). Transsphenoidal surgery is currently the first
line of treatment, and secondary options consist of irradiation
therapy either alone or in combination with adrenolytic agents
(10, 34, 35, 37). Unfortunately, none of the current treatment
modalities ensures a full and permanent cure, as evidenced by
the number of patients developing recurrent Cushing’s disease
(43). The absence of an effective medical treatment has
prompted physicians to explore new medical strategies, pref-
erably based on fundamental and (patho)physiological path-
ways, in the hope of increasing the curation chances in this
group of patients.
The physiological role of somatostatin (SS) in the regulation
of anterior pituitary function (5, 27, 41, 45), its equivocal
effects on ACTH release (6, 24), and the current use of SS
analogs in patients with anterior pituitary tumors (29), has led
to the exploration of SS analogs in patients with (recurrent)
Cushing’s disease. To date, five G protein-coupled SS recep-
tors have been cloned (sst1–sst5), and six gene products are
currently known (39, 45). The receptor subtypes sst1–5 produce
single gene products, whereas sst2A (long form) and sst2B
(short form) originate from a common precursor mRNA, which
is spliced at the carboxyl terminus (56). Although in vitro data
demonstrate the presence of sst expression in corticotroph
adenomas, the sst2-preferential analog octreotide (OCT) ap-
pears to inhibit ACTH release in Nelson’s syndrome and in
some patients harboring ectopic ACTH-producing tumors, but
rarely in patients with Cushing’s disease (13, 30). These
observations are in agreement with the observation that almost
all ACTH-secreting pituitary adenomas, i.e., patients with
untreated Cushing’s disease, cannot be visualized by SS recep-
tor (sst) scintigraphy using 111In-diethylenetriamine pentaace-
tic acid (DTPA) OCT (12, 28), whereas 111In-DTPA scintig-
raphy is positive in patients with Nelson’s syndrome (11, 12).
Apparently, ACTH release from corticotropinomas is sensitive
to OCT only in the absence of peripheral feedback regulation
by glucocorticoids, suggesting that the sst2 might be down-
regulated when cortisol levels are high. Additional in vitro
evidence for this hypothesis comes from studies using primary
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